BC Extra | Jan 2, 2020
Company News

Jan. 3 Company Quick Takes: Illumina, PacBio call off deal; plus Innovax, Innate, J&J-Pulmatrix, Intrexon, Janssen-Provention

Illumina ends pursuit of PacBio  Illumina Inc. (NASDAQ:ILMN) has terminated its $1.2 billion bid for Pacific Biosciences of California Inc. (NASDAQ:PACB) due to “continued uncertainty of the ultimate outcome,” more than a year after proposing...
BC Innovations | Oct 21, 2019
Emerging Company Profile

Verseau unveils tumor macrophage reprogramming strategy

Verseau is aiming to treat solid tumor patients who don't respond to T cell-targeting agents by reprogramming tumor-associated macrophages to make them immuno-stimulatory. Eight months after announcing a collaboration with 3SBio Inc. (HKSE:1530), Verseau Therapeutics...
BC Innovations | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
BC Innovations | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BC Innovations | Mar 8, 2019
Targets & Mechanisms

Flipping the switch in immuno-oncology

Tumor myeloid cells are emerging as prime candidates for filling a hole in the immuno-oncology tool box, offering targets that can simultaneously release the brakes and rev up the gas in the immune system. As...
BC Week In Review | Oct 19, 2018
Company News

GEn1E gains option to p38 MAPK inhibitor

GEn1E Lifesciences Inc. (Palo Alto, Calif.) gained an exclusive option to license a patent application from the University of Maryland Baltimore (Baltimore, Md.) covering methods and use of p38 mitogen-activated protein kinase (p38 MAPK; MAPK14)...
BC Week In Review | May 18, 2018
Financial News

EIP gets $20.5M to develop AD candidate

CNS company EIP Pharma LLC (Cambridge, Mass.) raised $20.5 million on May 16 in a series B round led by new investor Access Industries. Other individual investors participated. EIP told BioCentury it expects the funding...
BC Extra | May 16, 2018
Financial News

EIP gets $20.5M to develop AD candidate

CNS company EIP Pharma LLC (Cambridge, Mass.) raised $20.5 million in a series B round led by new investor Access Industries. Other individual investors participated. EIP told BioCentury it expects the funding to last through...
BC Week In Review | Jan 5, 2018
Company News

Array spins out Yarra to develop ARRY-797

Array BioPharma Inc. (NASDAQ:ARRY) spun out Yarra Therapeutics LLC (Boulder, Colo.) to develop ARRY-797. In 2016, Array reported data from a Phase II trial in patients with symptomatic dilated cardiomyopathy due to a lamin A/C...
BC Week In Review | Jan 5, 2018
Clinical News

Mereo reports Phase II data for COPD candidate acumapimod

Mereo BioPharma Group plc (LSE:MPH) reported top-line data from a Phase II trial in 282 patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) showing that low- and high-dose acumapimod (BCT-197) plus standard of...
Items per page:
1 - 10 of 163